Latest research and development trends in non-insulin anti-diabetics

Archives of Pharmacal Research

Volumn 36, Issue 2, 2013, Pages 145-153

  Cheon, Hyae Gyeong ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Anti diabetes; Insulin resistance; Insulin secretion; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ARHALOFENATE; BALAGLITAZONE; BMS 741672; CCX 140; DAPAGLIFLOZIN; EXENDIN 4; GSK 1292263A; INCB 13739; INCRETIN; INF 131; JTT 851; LIRAGLUTIDE; LY 2523199; MBX 2982; METFORMIN; PIOGLITAZONE; PSN 821; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TAK 875; TRIOLEX; UNCLASSIFIED DRUG; VGX 1027; VILDAGLIPTIN;

CATALYSIS; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; DRUG TOLERABILITY; FATTY ACID METABOLISM; GENE EXPRESSION; GENE OVEREXPRESSION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; VOMITING; WEIGHT REDUCTION;

EID: 84879507503     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0016-7     Document Type: Review

References (53)

1. Ali, A.A.; R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, and R.L. Jilka. 2005. Rosiglitazone causes bone loss in mice by suppressing osteoblast and bone formation. Endocrinology 146: 1226-1235.
2. Aliquier, T.; and V. Poitout. 2009. GPR40: Good cop, or bad cop? Diabetes 58: 1035-1036.
3. Berger, J.; and D.E. Moller. 2002. The mechanisms of action of PPARs. Annual Review of Medicine 53: 409-435.
4. Birch, A.; L.K. Buckett, and A.V. Turnbull. 2010. DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Current Opinion in Drug Discovery & Development 13: 489-496.
5. Blonde, L. 2010. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. The American Journal of Medicine 123(3A): S12-S18.
6. Brown, J.M.; and L.L. Rudel. 2010. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Current Opinion in Lipidology 21: 192-197.
7. Carpino, P.A.; and B. Goodwin. 2010. Diabetes area participation analysis: A review of companies and targets described in the 2008-2010 patent literature. Expert Opinion on Therapeutic Patents 20: 1627-1651.
8. Cases, S.; P. Zhou, J.M. Shillingford, B.S. Wiseman, J.D. Fish, C.S. Angle, L. Hennighausen, Z. Werb, and R.V. Farese Jr. 2004. Development of the mammary gland requires DGAT-1 expression in stromal and epithelial tissues. Development 131: 3047-3055.
9. Chen, H.C.; S.J. Smith, Z. Ladha, D.R. Jensen, L.D. Ferreira, L.K. Pulawa, J.S. McGuire, R.E. Pitas, R.H. Eckel, and R.V. Farese Jr. 2002. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. The Journal of Clinical Investigation 109: 1049-1055.
10. Christesen, H.; B. Jacobsen, S. Odili, C. Buettger, A. Cuesta-Munoz, T. Hansen, K. Brusgaard, O. Massa, M.A. Magnuson, C. Shiota, F.M. Matschinsky, and F. Barbetti. 2002. The second activating glucokinase mutation (A456 V): Implications for glucose homeostasis and diabetes therapy. Diabetes 51: 1240-1246.
11. Chu, Z.L.; C. Carroll, J. Alfonson, V. Gutierrez, H. He, A. Lucman, M. Pedraza, H. Mondala, H. Gao, D. Bagnol, R. Chen, R.M. Jones, D.P. Behan, and J. Leonard. 2008. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149: 2038-2047.
12. Cuesta-Munoz, A.L.; H. Huopio, T. Otonkoski, J.M. Gomez-Zumaquero, K. Nanto-Salonen, J. Rahier, S. Lopez-Enriquez, M.A. Garcia-Gimeno, P. Sanz, F.C. Soriguer, and M. Laakso. 2004. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53: 2164-2168.
13. Deacon, C.F.; M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J.J. Holst. 1995. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
14. Doshi, L.S.; M.K. Brahma, U.A. Bahirat, A.V. Dixit, and K.V.S. Nemmani. 2010. Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents. Expert Opinion on Investigational Drugs 19: 489-512.
15. Elchebly, M.; P. Payette, E. Michaliszyn, W. Cromlish, S. Collins, A.L. Loy, D. Normandin, A. Cheng, J. Himms-Hagen, C.C. Chan, C. Ramachandran, M.J. Gresser, M.L. Tremblay, and B.P. Kennedy. 1999. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphates-1B gene. Science 283: 1544-1548.
16. Enoch, H.G.; and P. Strittmatter. 1978. Role of tyrosyl and arginyl residues in rat liver microsomal stearylcoenzyme A desaturase. Biochemistry 17: 4927-4932.
17. Goldfine, A.B.; V. Fonseca, and S.E. Shoelson. 2011. Therapeutic approaches to target inflammation in type 2 diabetes. Clinical Chemistry 57: 162-167.
18. Guan, Y.; C. Hao, D.R. Cha, R. Rao, W. Lu, D.E. Kohan, M.A. Magnuson, R. Redha, Y. Zhang, and M.D. Breyer. 2005. Thiazolidinediones expand body fluid volume through PPAR-gamma stimulation of ENaC-mediated renal salt absorption. Nature Medicine 11: 861-866.
19. Holst, J.J. 2007. The physiology of glucagon-like peptide 1. Physiological Reviews 87: 1409-1439.
20. Hotamisligil, G.S. 2006. Inflammation and metabolic disorders. Nature 444: 860-867.
21. Hotamisligil, G.S.; P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. The Journal of Clinical Investigation 95: 2409-2415.
22. Itoh, Y.; Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa, and M. Fujino. 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173-176.
23. Iversen, L.F.; K.B. Moller, A.K. Pedersen, G.H. Peters, A.S. Petersen, H.S. Andersen, S. Branner, S.B. Mortensen, and N.P. Moller. 2002. Structure determination of T cell protein tyrosine phosphatase. Journal of Biological Chemistry 277: 19982-19990.
24. Kanai, Y.; W.S. Lee, G. You, D. Brown, and M.A. Hediger. 1994. The human kidney low affinity Na +/glucose cotransporter SGLT-2. Delineation of the major renal reabsorptive mechanism for d-glucose. The Journal of Clinical Investigation 93: 397-404.
25. Kanda, H.; S. Tateya, Y. Tamori, K. Kotani, K. Hiasa, R. Kitazawa, S. Kitazawa, H. Miyachi, S. Maeda, K. Egashira, and M. Kasuga. 2006. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. The Journal of Clinical Investigation 116: 1494-1505.
26. Kaszubska, W.; H.D. Falls, V.G. Schaefer, D. Haasch, L. Frost, P. Hessler, P.E. Kroeger, D.W. White, M.R. Jirousek, and J.M. Trevillyan. 2002. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Molecular and Cellular Endocrinology 195: 109-118.
27. King, A.J.; A.S. Judd, and A.J. Souers. 2010. Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents. Expert Opinion on Therapeutic Patents 20: 19-29.
28. Koren, S.; and I.G. Fantus. 2007. Inhibition of the protein tyrosine phosphatase PTP-1B: potential therapy for obesity, insulin resistance and type 2 diabetes mellitus. Best Practice & Research, Clinical Endocrinology & Metabolism 21: 621-640.
29. Kotelevtsev, Y.; M.C. Holmes, A. Burchell, P.M. Houston, D. Schmoll, P. Jamieson, R. Best, R. Brown, C.R. Edwards, J.R. Seckl, and J.J. Mullins. 1997. 11beta-hydroxysteroid dehydrogenase type 2 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proceedings of the National Academy of Sciences of the United States of America 94: 14924-14929.
30. Kusunoki, J.; A. Kanatani, and D.E. Moller. 2006. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine 29: 91-100.
31. Larsen, C.M.; M. Faulenbach, A. Vaag, A. Volund, J.A. Eheses, B. Seifert, T. Mandrup-Poulsen, and M.Y. Donath. 2007. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine 356: 1517-1526.
32. Leger, S.; W.C. Black, D. Deschenes, S. Dolman, J.P. Falgueyret, M. Gagnon, S. Guiral, Z. Huang, J. Guay, Y. Leblanc, C.S. Li, F. Masse, R. Oballa, and L. Zhang. 2010. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorganic & Medicinal Chemistry Letters 20: 499-502.
33. Liu, G. 2009. Stearoyl-CoA desaturase inhibitors: update on patented compounds. Expert Opinion on Therapeutic Patents 19: 1169-1191.
34. Matschinsky, F.M.; B. Zelent, N.M. Doliba, K.H. Kaestner, J.M. Vanderkooi, J. Grimsby, S.J. Berthel, and R. Sarabu. 2011. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handbook of Experimental Pharmacology 203: 357-401.
35. Matschinsky, F.M.; M.A. Magnuson, D. Zelent, T.L. Jetton, N. Doliba, Y. Han, R. Taub, and J. Grimsby. 2006. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55: 1-12.
36. Miyazaki, M.; Y.C. Kim, M.P. Gray-Keller, A.D. Attie, and J.M. Ntambi. 2000. The biosynthesis of hepatic cholesterol esters and triglyceride is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. Journal of Biological Chemistry 275: 30132-30138.
37. Miyazaki, M.; A. Dobrzyn, H. Sampath, S.H. Lee, W.C. Man, K. Chu, J.M. Peters, F.J. Gonzalez, and J.M. Ntambi. 2004. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 279: 35017-35024.
38. Mudaliar, S.; A.R. Chang, and R.R. Henry. 2003. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocrine Practice 9: 406-416.
39. Ntambi, J.M.; M. Miyazaki, J.P. Stoehr, H. Lan, C.M. Kendziorski, B.S. Yandell, Y. Song, P. Cohen, J.M. Friedman, and A.D. Attie. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proceedings of the National Academy of Sciences of the United States of America 99: 11482-11486.
40. Page, R.I.; W.S. Gozansky, and J.M. Ruscin. 2003. Possible exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 23: 945-954.
41. Rask, E.; T. Olsson, S. Soderberg, R. Andrew, D.E. Livingstone, D. Johnson, and B.R. Walker. 2001. Tissue-specific dysregulation of cortisol metabolism in human obesity. Journal of Clinical Endocrinology and Metabolism 86: 1418-1421.
42. Ryden, L.; E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, K. Malmberg, S. Priori, J. Osergren, J. Tuomilehto, I. Thrainsdottir, I. Vanhorebeek, M. Stramba-Badiale, P. Lingren, Q. Qiao, S.G. Priori, and J.J. Blanc. 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. European Heart Journal 28: 88-126.
43. Semple, R.K.; V.K.K. Chatterjee, and S. O'Rahilly. 2006. PPAR gamma and human metabolic disease. The Journal of Clinical Investigation 116: 581-589.
44. Soga, T.; T. Ohishi, T. Matsui, T. Saito, M. Matsumoto, J. Takasaki, S. Matsumoto, M. Kamohara, H. Hiyama, S. Yoshida, K. Momose, Y. Ueda, H. Matsushime, M. Kobori, and K. Furuichi. 2005. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochemical and Biophysical Research Communications 326: 744-751.
45. Steneberg, P.; N. Rubins, R. Bartoov-Shifman, M.D. Walker, and H. Edlund. 2005. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metabolism 1: 245-258.
46. Stone, S.J.; H.M. Myers, S.M. Watkins, B.E. Brown, K.R. Feingold, P.M. Elias, and R.V. Farese Jr. 2004. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. Journal of Biological Chemistry 279: 11767-11776.
47. Tannin, G.M.; A.K. Agarwal, C. Monder, M.I. New, and P.C. White. 1991. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. Journal of Biological Chemistry 266: 16653-16658.
48. Tilg, H.; and A.R. Moschen. 2008. Inflammatory mechanisms in the regulation of insulin resistance. Molecular Medicine 14: 222-231.
49. Vilsbell, T.; H. Tferso, T. Kraup, and J.J. Holst. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. The Journal of Clinical Endocrinology and Metabolism 88: 220-224.
50. Wild, S.; G. Roglic, A. Green, R. Sicree, and H. King. 2004. Global prevalence of diabetes: Estimates for the year 2000 and projection for 2030. Diabetes Care 27: 1047-1053.
51. Weisberg, S.P.; D. Hunter, R. Huber, J. Lemieux, S. Slaymaker, K. Vaddi, I. Charo, R.L. Leibel, and A.W. Ferrante Jr. 2006. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. The Journal of Clinical Investigation 116: 115-124.
52. Yen, C.L.; S.J. Stone, S. Koliwad, C. Harris, and R.V. Farese Jr. 2008. Thematic review series: Glycerolipids, DGAT enzymes and triacylglycerol biosynthesis. Journal of Lipid Research 49: 2283-2301.
53. Yu, X.X.; S.F. Murray, S.K. Pandey, S.L. Booten, D. Bao, X.Z. Song, S. Kelly, S. Chen, R. Mckay, B.P. Monia, and S. Bhanot. 2005. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42: 362-371.